INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune(TM)
December 8, 2022
CEO Joseph Johnson discusses the creation of digital tools that allow transparency within the boating market, making waves by setting standards for industry sales.